ArticlePloS one
Localization, Shedding, Regulation and Function of Aminopeptidase N/CD13 on Fibroblast like Synoviocytes.
Article in PloS one. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 23 citations in OpenAlex.
- Soluble CD13 in systemic sclerosis: clinical observations and transcriptomic insights from peripheral blood.Arthritis research & therapy · 2026Article
- Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants.Viruses · 2025Review
- Soluble CD13 is a potential mediator of neutrophil-induced thrombogenic inflammation in SARS-CoV-2 infection.JCI insight · 2025Article
- Targeting CD13/Aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis.Arthritis & rheumatology (Hoboken, N.J.) · 2025Article
- New molecular targets in the treatment of rheumatoid arthritis.Current opinion in rheumatology · 2024Review
- Aminopeptidase N/CD13 Crosslinking Promotes the Activation and Membrane Expression of Integrin CD11b/CD18.Biomolecules · 2023Article
- The Role of the Ectopeptidase APN/CD13 in Cancer.Biomedicines · 2023Review
- Elucidating a fresh perspective on the interplay between exosomes and rheumatoid arthritis.Frontiers in cell and developmental biology · 2023Review
- Serum-derived extracellular vesicles: Novel biomarkers reflecting the disease severity of COVID-19 patients.Journal of extracellular vesicles · 2022Article
- The enzymes in COVID-19: A review.Biochimie · 2022Review
- Soluble CD13 induces inflammatory arthritis by activating the bradykinin receptor B1.The Journal of clinical investigation · 2022Article
- Proteomic Analysis Reveals Differential Expression Profiles in Idiopathic Pulmonary Fibrosis Cell Lines.International journal of molecular sciences · 2022Article
- RA Fibroblast-Like Synoviocytes Derived Extracellular Vesicles Promote Angiogenesis by miRNA-1972 Targeting p53/mTOR Signaling in Vascular Endotheliocyte.Frontiers in immunology · 2022Article
- Increased long noncoding RNA LINK-A contributes to rheumatoid synovial inflammation and aggression.JCI insight · 2021Article
- Coronavirus Receptors as Immune Modulators.Journal of immunology (Baltimore, Md. : 1950) · 2021Review
- Synovial fluid peptidase activity as a biomarker for knee osteoarthritis clinical progression.Bone & joint research · 2020Article
- CD13/Aminopeptidase N Is a Potential Therapeutic Target for Inflammatory Disorders.Journal of immunology (Baltimore, Md. : 1950) · 2020Review
- Angiogenic and Arthritogenic Properties of the Soluble Form of CD13.Journal of immunology (Baltimore, Md. : 1950) · 2019Article
- Emerging role of extracellular vesicles in musculoskeletal diseases.Molecular aspects of medicine · 2018Review
- Synovial cellular and molecular markers in rheumatoid arthritis.Seminars in immunopathology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Aminopeptidase N/CD13 is highly expressed by fibroblast like synoviocytes (FLS) and may play a role in rheumatoid arthritis (RA). CD13 was previously detected in human synovial fluid where it was significantly increased in RA compared to osteoarthritis. In this study we found that CD13 in biological fluids (plasma, synovial fluid, FLS culture supernatant) is present as both a soluble molecule and on extracellular vesicles, including exosomes, as assessed by differential ultracentrifugation and density gradient separation. Having determined CD13 could be released as a soluble molecule from FLS, we examined potential mechanisms by which CD13 might be shed from the FLS membrane. The use of protease inhibitors revealed that CD13 is cleaved from the FLS surface by metalloproteinases. siRNA treatment of FLS revealed one of those proteases to be MMP14. We determined that pro-inflammatory cytokines (TNFα, IFNγ, IL-17) upregulated CD13 mRNA in FLS, which may contribute to the increased CD13 in RA synovium and synovial fluid. Inhibition of CD13 function by either inhibitors of enzymatic activity or anti-CD13 antibodies resulted in decreased growth and diminished migration of FLS. This suggests that CD13 may be involved in the pathogenic hyperplasia of RA FLS. This data expands potential roles for CD13 in the pathogenesis of RA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.